| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operations was $11.6 milli... |
| 13 Oct 2026 |
8-K: Other Events
- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia |
| 31 Aug 2026 |
8-K: Other Events
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans |
| 17 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representatives (the “Representatives”) of the several underwriters |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby |
| 22 Jul 2026 |
8-K: Other Events
- If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 26 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the BridgeBio Pharma, Inc. Third Amended and Restated 2021 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consu... |
| 27 May 2026 |
8-K: Other Events
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 com... |
| 13 May 2026 |
8-K: Other Events
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 |
| 08 May 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On May 7, 2026, BridgeBio Pharma, Inc. (the “Company”) filed a registration statement on Form S-3ASR (File No.: 333-295678, the “Registration Statement”) under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”) wit... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
-$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum |
| 30 Mar 2026 |
8-K: Other Events
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation... |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
-$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively |
| 12 Feb 2026 |
8-K: Other Events
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia |
| 21 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE dated as of January 21, 2026 between BRIDGEBIO PHARMA, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as trustee (the “Trustee... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Forward Looking Statements and Disclaimer The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Se... |
| 29 Oct 2025 |
8-K: Other Events
- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition
-$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue |
| 27 Oct 2025 |
8-K: Other Events
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies |
Loading...